Literature DB >> 22976127

Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals.

J Du, Y Liu, B Meline, G Kong, L X Tan, J C Lo, J Wang, E Ranheim, L Zhang, Y I Chang, M J Ryu, J F Zhang, J Zhang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22976127      PMCID： PMC3602969          DOI： 10.1038/leu.2012.251

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets.

Authors:  U Protin; T Schweighoffer; W Jochum; F Hilberg
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

2.  A positive feedback loop couples Ras activation and CD44 alternative splicing.

Authors:  Chonghui Cheng; Michael B Yaffe; Phillip A Sharp
Journal:  Genes Dev       Date:  2006-07-01       Impact factor: 11.361

3.  Antibody-induced shedding of CD44 from adherent cells is linked to the assembly of the cytoskeleton.

Authors:  M Shi; K Dennis; J J Peschon; R Chandrasekaran; K Mikecz
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

4.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells.

Authors:  Liqing Jin; Kristin J Hope; Qiongli Zhai; Florence Smadja-Joffe; John E Dick
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

5.  Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.

Authors:  Daniela S Krause; Katherine Lazarides; Ulrich H von Andrian; Richard A Van Etten
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

6.  Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

Authors:  Jinyong Wang; Yangang Liu; Zeyang Li; Zhongde Wang; Li Xuan Tan; Myung-Jeom Ryu; Benjamin Meline; Juan Du; Ken H Young; Erik Ranheim; Qiang Chang; Jing Zhang
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

7.  Activation of CD44 facilitates DNA repair in T-cell lymphoma but has differential effects on apoptosis induced by chemotherapeutic agents and ionizing radiation.

Authors:  C Chen; M-C Chang; R-K Hsieh; Y-F Chang; J Lin; K-W Tsan
Journal:  Leuk Lymphoma       Date:  2005-12

8.  CD44 expression in T-cell lymphoblastic leukemia.

Authors:  G B Cavalcanti Júnior; W Savino; M S Pombo-de-Oliveira
Journal:  Braz J Med Biol Res       Date:  1994-09       Impact factor: 2.590

9.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

10.  Monoclonal antibodies to CD44 and their influence on hyaluronan recognition.

Authors:  Z Zheng; S Katoh; Q He; K Oritani; K Miyake; J Lesley; R Hyman; A Hamik; R M Parkhouse; A G Farr; P W Kincade
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539
View more
  14 in total

1.  Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.

Authors:  G Kong; Y-I Chang; A Damnernsawad; X You; J Du; E A Ranheim; W Lee; M-J Ryu; Y Zhou; Y Xing; Q Chang; C E Burd; J Zhang
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528

2.  Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.

Authors:  A Staffas; C Karlsson; M Persson; L Palmqvist; M O Bergo
Journal:  Leukemia       Date:  2014-11-05       Impact factor: 11.528

3.  Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.

Authors:  Y-I Chang; X You; G Kong; E A Ranheim; J Wang; J Du; Y Liu; Y Zhou; M-J Ryu; J Zhang
Journal:  Leukemia       Date:  2015-03-24       Impact factor: 11.528

4.  Dnmt3a haploinsufficiency cooperates with oncogenic Kras to promote an early-onset T-cell acute lymphoblastic leukemia.

Authors:  Yuan-I Chang; Guangyao Kong; Erik A Ranheim; Po-Shu Tu; Yi-Shan Yu; Jing Zhang
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

5.  Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.

Authors:  Jingfang Zhang; Erik A Ranheim; Juan Du; Yangang Liu; Jinyong Wang; Guangyao Kong; Jing Zhang
Journal:  J Biol Chem       Date:  2015-06-16       Impact factor: 5.157

6.  Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Authors:  Guangyao Kong; Mark Wunderlich; David Yang; Erik A Ranheim; Ken H Young; Jinyong Wang; Yuan-I Chang; Juan Du; Yangang Liu; Sin Ruow Tey; Xinmin Zhang; Mark Juckett; Ryan Mattison; Alisa Damnernsawad; Jingfang Zhang; James C Mulloy; Jing Zhang
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

7.  Kras is Required for Adult Hematopoiesis.

Authors:  Alisa Damnernsawad; Guangyao Kong; Zhi Wen; Yangang Liu; Adhithi Rajagopalan; Xiaona You; Jinyong Wang; Yun Zhou; Erik A Ranheim; Hongbo R Luo; Qiang Chang; Jing Zhang
Journal:  Stem Cells       Date:  2016-03-28       Impact factor: 6.277

8.  Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.

Authors:  Guangyao Kong; Juan Du; Yangang Liu; Benjamin Meline; Yuan-I Chang; Erik A Ranheim; Jinyong Wang; Jing Zhang
Journal:  J Biol Chem       Date:  2013-05-14       Impact factor: 5.157

9.  Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.

Authors:  Jinyong Wang; Guangyao Kong; Yangang Liu; Juan Du; Yuan-I Chang; Sin Ruow Tey; Xinmin Zhang; Erik A Ranheim; Marc K Saba-El-Leil; Sylvain Meloche; Alisa Damnernsawad; Jingfang Zhang; Jing Zhang
Journal:  Blood       Date:  2013-05-17       Impact factor: 22.113

10.  Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.

Authors:  Xiaona You; Fabao Liu; Moritz Binder; Alexis Vedder; Terra Lasho; Zhi Wen; Xin Gao; Evan Flietner; Adhithi Rajagopalan; Yun Zhou; Christy Finke; Abhishek Mangaonkar; Ruiqi Liao; Guangyao Kong; Erik A Ranheim; Nathalie Droin; Anthony M Hunter; Sergey Nikolaev; Maria Balasis; Omar Abdel-Wahab; Ross L Levine; Britta Will; Kalyan Vara Ganesh Nadiminti; David Yang; Klaus Geissler; Eric Solary; Wei Xu; Eric Padron; Mrinal M Patnaik; Jing Zhang
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.